Evidence map›Paper›PMID 34713591›Full record

ArticleJournal of the International AIDS Society2021

Differentiated service delivery models among PLHIV in Akwa Ibom and Cross River States, Nigeria during the COVID-19 pandemic: descriptive analysis of programmatic data.

Olusola Sanwo, Navindra E Persaud, Pius Nwaokoro, Augustine Idemudia, Uduak Akpan, Otoyo Toyo, Philip Imohi, Titilope Badru, Chika Obiora-Okafo, Chimamaka Excellence Uzochukwu and 9 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Olusola SanwoFHI 360, Abuja, Nigeria.
Navindra E PersaudFHI 360, Washington, DC, USA.
Pius NwaokoroFHI 360, Abuja, Nigeria.
Augustine IdemudiaAHNi, Abuja, Nigeria.
Uduak AkpanAHNi, Abuja, Nigeria.
Otoyo ToyoAHNi, Abuja, Nigeria.
Philip ImohiAHNi, Abuja, Nigeria.
Titilope BadruFHI 360, Abuja, Nigeria.
Chika Obiora-OkafoFHI 360, Abuja, Nigeria.
Chimamaka Excellence UzochukwuAHNi, Abuja, Nigeria.
Oluwapelumi AliuAHNi, Abuja, Nigeria.
Kolawole OlatunbosunFHI 360, Abuja, Nigeria.
Satish Raj PandeyFHI 360, Abuja, Nigeria.
Hadiza KhamofuFHI 360, Abuja, Nigeria.
Robert ChiegilFHI 360, Washington, DC, USA.
Ezekiel JamesUSAID, Abuja, Nigeria.
Isa IyortimUSAID, Abuja, Nigeria.
Dorothy OquaHoward University Global Initiative, Abuja, Nigeria.
Moses BateganyaFHI 360, Washington, DC, USA.
Achieving Health Nigeria Initiative · NGFamily Health International 360 · USZero to Three · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe rapid increase in the number of people living with HIV (PLHIV) on antiretroviral therapy (ART) in Akwa Ibom and Cross River states in Nigeria led to overcrowding at clinics. Patients were devolved to receive ART refills through five differentiated service delivery (DSD) models: fast-track (FT), adolescent refill clubs (ARCs), community pharmacy ART refill programs (CPARPs), community ART refill clubs (CARCs) and community ART refill groups (CARGs) designed to meet the needs of different groups of PLHIV. In the context of COVID-19-related travel restrictions, out-of-facility models offered critical mechanisms for continuity of treatment. We compared retention and viral suppression among those devolved to DSD with those who continued standard care at facilities.

methodsA retrospective cohort study was conducted among patients devolved to DSD from January 2018 to December 2020. Bivariate analyses were conducted to assess differences in retention and viral suppression by socio-demographic characteristics. Kaplan-Meier assessed retention at 3, 6, 9 and 12 months. Differences in proportions were compared using the chi-square test; a p-value of <0.05 was considered significant.

resultsA total of 40,800 PLHIV from 84 facilities received ART through the five models: CARC (53%), FT (19.1%), ARC (12.1%), CPARP (10.4%) and CARG (5.4%). Retention rates at 6 months exceeded 96% for all models compared to 94% among those continuing standard care. Among those using DSD, retention rate at 12 months was higher among adults than children (97.8% vs. 96.7%, p = 0.04). No significant sex differences in retention rates were found among those enrolled in DSD. Viral suppression rates among PLHIV served through DSD were significantly higher among adults than children (95.4% vs. 89.2%; p <0.01). Among adults, 95.4% enrolled in DSD were virally suppressed compared to 91.8% of those in standard care (p <0.01). For children, 89.2% enrolled in DSD were virally suppressed compared to 83.2% in standard care (p <0.01).

conclusionsPLHIV receiving ART through DSD models had retention but higher viral suppression rates compared to those receiving standard care. Expanding DSD during COVID-19 has helped ensure uninterrupted access to ART in Nigeria. Further scale-up is warranted to decongest facilities and improve clinical outcomes.

Indexed as

Anti-HIV AgentsCOVID-19HIV InfectionsAdolescentAdultChildFemaleHumansMaleNigeriaPandemicsRetrospective StudiesSARS-CoV-2Anti-HIV AgentsCOVID-19differentiated service deliveryNigeriapeople living with HIVtreatment retentionviral suppression

Identifiers

PMID34713591
PMCPMC8554211
OpenAlexW3209556716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.